Oramed Pharmaceuticals Logo
US68403P2039
A1CTNU
ORMP.TA

Oramed Pharmaceuticals

Previsão

Comprar
  6
Manter
  2
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Lifeward shareholders approve partnership with Oramed and potential capital injection

    Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » Mais em de.investing.com


  • Oramed receives $18 million from Scilex and announces cash dividend

    Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » Mais em de.investing.com


  • Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years

    Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » Mais em de.investing.com


  • Oramed completes repurchase of Scilex warrants for $28.5m

    Oramed received a total of $28.5 million from Scilex for the repurchase of warrants to acquire 6,500,000 Scilex common shares (two tranches: 3,370,000 shares for $14 million and 3,130,000 shares for $13 million, plus $1.5 million in option fees). The warrants had an exercise price of $0.01 and were repurchased under an agreement disclosed in July. In addition, Oramed repurchased 1,155,367 of its own common shares for about $2.58 million and ended a joint venture with HTIT/Technowl; the company now plans to continue its oral insulin program independently and to initiate a new U.S. study. » Mais em de.investing.com


  • Oramed buys back HTIT shares and ends joint venture

    Oramed repurchased 1,155,367 common shares of Hefei Tianhui Biotech (HTIT) at $2.23 each (about $2.58 million) and had the shares cancelled. The company terminated the joint-venture agreement with HTIT and Technowl after HTIT failed to meet closing conditions. Oramed released preliminary, unaudited financials as of September 30, 2025, and launched a new U.S. study for its oral insulin program with 60 identified high responders. It also completed the first tranche of an option repurchase agreement with Scilex (3,130,000 shares for $13 million) and increased the number of authorized shares under its stock option plan by 2,000,000 to 9,500,000. » Mais em de.investing.com

Em 2026, Oramed Pharmaceuticals já distribuiu € 0,21 em dividendos. A última distribuição ocorreu em janeiro.

Dados financeiros

No último trimestre, Oramed Pharmaceuticals registou receitas de € 0 e um ganho líquido de € 16,25 mi

(EUR) setembro de 2026
YoY
Receitas 0 -
Ganho bruto 0 100,00%
Ganho líquido 16,25 mi 60,59%
EBITDA 24,99 mi 50,69%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 141,48 mi
Número de ações
43,49 mi
Máximo/mínimo de 52 semanas
€ 4,99 - € 2,30
Rentabilidade de dividendos
6,00%
Dividendos TTM
€ 0,21
Beta
1,28
PER (PE Ratio)
1,02
PEG (PEG Ratio)
0,00
P/VC (PB Ratio)
0,44
P/V (PS Ratio)
0,00

Perfil da empresa

A Oramed Pharmaceuticals Inc. dedica-se à investigação e desenvolvimento de soluções farmacêuticas para o tratamento da diabetes e para a utilização de cápsulas ou comprimidos ingeríveis por via oral na administração de polipéptidos. O seu produto emblemático e de propriedade exclusiva é o ORMD-0801, uma cápsula de insulina ingerível por via oral, que concluiu os ensaios clínicos de fase II para o tratamento de indivíduos com diabetes. A empresa desenvolve também o ORMD-0901, uma cápsula oral de peptídeo semelhante ao glucagon-1, que concluiu os ensaios clínicos de fase I para o tratamento da diabetes tipo 2; e um tratamento para a perda de peso sob a forma de uma cápsula oral de leptina. A empresa era anteriormente conhecida como Integrated Security Technologies, Inc. e mudou o seu nome para Oramed Pharmaceuticals Inc. em abril de 2006. A Oramed Pharmaceuticals Inc. foi fundada em 2002 e tem sede em Nova Iorque, Nova Iorque.

Nome
Oramed Pharmaceuticals
CEO
Nadav Kidron
Sede New York City, ny
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
01/05/2007
Colaboradores 13

Análise aprofundada

Símbolos de ticker

Bolsa Símbolo
Tlv
ORMP.TA
NASDAQ
ORMP
Frankfurt
OJU1.F
Düsseldorf
OJU1.DU
München
OJU1.MU
🍪

Parqet  utiliza cookies. Saber mais